Multiresistant organisms at the front line

Abstract

Multiresistant bacterial pathogens such as methicillin-resistant Staphylococcus aureus, multiresistant Streptococcus pneumoniae, vancomycin-resistant enterococci and multiresistant Pseudomonas aeruginosa are being seen with increasing frequency in the community and not just in hospital practice. Treatment options for infections caused by these pathogens are limited, but in most cases a suitable drug can be found. In particular, there are options for the treatment of the community-associated strains of MRSA, such as trimethoprim-sulfamethoxazole, and often macrolides or lincosamides.